Physician profile
Saroj Brar
NPI 1487733366
$13,084.25
in general payments reported to CMS, 2019-2025
20 companies · $2,780 in 2025
The $2,780 reported for 2025 was more than what 92% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,503 · 2020: $578 · 2021: $1,827 · 2022: $842 · 2023: $1,608 · 2024: $1,947 · 2025: $2,780.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,225 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,225.15 |
| Education | $109.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $2,759.23 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Janssen Pharmaceuticals, INC | $2,448.51 | 2019-2025 | Invega Sustenna, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $1,500.37 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $1,393.67 | 2019-2025 | Rexulti, Abilify Maintena |
| Sunovion Pharmaceuticals INC. | $1,207.31 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $973.56 | 2021-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $745.67 | 2025 | Cobenfy |
| Abbvie INC. | $519.29 | 2021-2025 | Vraylar |
| Allergan, INC. | $468.13 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $314.01 | 2019-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $233.35 | 2019-2025 | Fanapt, Hetlioz |
| Tempus Ai, INC | $134.53 | 2024 | |
| Indivior INC. | $124.25 | 2019-2024 | Perseris |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $102.14 | 2020-2022 | |
| Axsome Therapeutics, INC. | $74.85 | 2023-2025 | Auvelity |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $31.34 | 2023-2025 | Rexulti |
| Luye Pharma (USA) LTD. | $22.33 | 2025 | Erzofri Extended-Release |
| Avanir Pharmaceuticals, INC. | $20.53 | 2019 | |
| Merck Sharp & Dohme LLC | $11.18 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saroj Brar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.